Bavarian Nordic (BAVA)

Business description

Bavarian Nordic is a Danish biotech focused on developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Its lead products are Prostvac (prostate cancer) and Imvamune (smallpox).

Share price chart

Share chart

Stock data

Market cap.DKK4961.4m
Last closeDKK190.00
High / Low (52 weeks)DKK193.5 / DKK66.0
Stock market listingOMX
Forecast net cash (DKKm)401
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual68.165.9183.6
Relative *75.268.5133.7

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Achillion Pharmaceuticals Acorda Therapeutics
Actinium Pharmaceuticals Active Biotech
Addex Therapeutics Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
Agennix Alchemia
Alexza Pharmaceuticals Algeta
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Alnylam Pharmaceuticals Amarantus BioScience
Amarin Amplifon
AmpliPhi Biosciences Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Arena Pharmaceuticals Argos Therapeutics
Ariad Pharmaceuticals Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Astex Pharmaceuticals
Athersys AVEO Pharmaceuticals
Avita Medical Basilea
Bellus Health Benitec Biopharma
BioAlliance Pharma BioCryst Pharmaceuticals
BioInvent BioLight Life Sciences Inv
BioLineRx Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio BTG
Can-Fite BioPharma Capstone Therapeutics
Cardio3 BioSciences CARMAT
Celldex Therapeutics Cellectis
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen
Clinuvel Consort Medical
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
EKF Diagnostics Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Futura Medical
Galapagos Galmed Pharmaceuticals
Genfit Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunodiagnostic Systems Holdings ImmuPharma
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Invion
Ion Beam Applications Ipsogen
Ironwood Pharmaceuticals Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Ligand Pharmaceuticals Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
MolMed Mologen AG
MorphoSys Nanobiotix
Nanosonics Nektar Therapeutics
Neovacs Newron Pharmaceuticals
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novogen
NPS Pharmaceuticals Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo OvaScience
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon Pharmacyclics
Pharmaxis Pharming Group
Photocure Phylogica
Prima BioMed ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Regeneus
ReNeuron Group Resverlogix
REVA Medical Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals Tekmira
TESARO Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Topotarget Transgene
Trillium Therapeutics Trimel Pharmaceuticals
UCB UDG Healthcare
uniQure NV United Drug
Vectura Verastem
Verisante Technology Vernalis
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus WaferGen Biosystems
Wilex Xencor
Zafgen Zealand Pharma
Zeltia Ziopharm Oncology
Y/E Dec Revenue (DKKm) EBITDA (DKKm) PBT (DKKm) EPS (øre) P/E (x) P/CF (x)
2012A 1017.0 (32.0) (49.0) (92.0) N/A 1.6
2013A 1213.0 181.0 154.0 38.8 4.9 0.3
2014E 1233.0 80.0 52.0 21.0 9.0 1.1
2015E 645.0 (51.0) (109.0) (44.5) N/A N/A

Last updated on 25/09/2014

Investment summary

Option exercise for the second portion of the Imvamune smallpox vaccine delivery contract to the US government unlocks valuation upside and confirms the strength of the relationship. Other recent developments in the profitable infectious disease division include a first commercial Canadian Imvamune order and increased US government funding for early-stage foot and mouth disease and Ebola programmes, with development of the latter being accelerated. Data from the Phase III PROSPECT prostate cancer trial of Prostvac – the main value driver of the cancer vaccines division – are not expected until H216; however, past and upcoming major conference updates on potential synergies with immune checkpoint inhibitors are contributing to a continuing active dialogue with potential partners.

Last updated on 30/09/2014

Industry outlook

The prostate cancer market is highly dynamic with various newly approved therapies; further Prostvac clinical data will be important in giving further insight into its commercial potential. Imvamune is a non-replicating third-generation smallpox vaccine that does not elicit comparable safety issues to previous generations; future US, European and Canadian orders are expected.

Last updated on 30/09/2014

Key management

Gerard van Odijk, Chairman
Paul Chaplin, CEO
Ole Larsen, CFO
Rolf Sass, IR

Company address

Hejreskovvej 10A
DK-3490 Kvistgaard
Denmark
View website